Paolo Tarantino· @PTarantinoMD · X·· 2 days agoScore90
Body
🇨🇳HORIZON-Breast06: Trastuzumab rezatecan widely outperformed chemo in endocrine-refractory HR+ MBC (PFS 16.6 vs 6.8 months, HR 0.25, p=0<0.01). Definitely passes the truck test. No significant OS, likely due to crossover of some patients to TOPO1 ADCs. #ESMO26 #ESMOAmbassadors
2222 views · 27 likes · 12 reposts · 1 reply
Conference abstracts
LBA13matched by Proffered paper 1: Breast cancer, early and advanced stage
Trastuzumab rezetecan (SHR-A1811) in HER2-low advanced breast cancer (BC): A randomized, phase 3 study (HORIZON-Breast06)
https://esmocongress.esmo.orgReplies in this thread
- Arturo LoAIza-Bonilla, MD MSEd@DrArturoAI
@PTarantinoMD 🛻 ✅
Source: Paolo Tarantino · x.com